1. Loh RK, Vale S, McLean-Tooke A. Quantitative serum immunoglobulin tests. Aust Fam Physician. 2013; 42:195–198.
2. Winter WE, Hardt NS, Fuhrman S. Immunoglobulin E: importance in parasitic infections and hypersensitivity responses. Arch Pathol Lab Med. 2000; 124:1382–1385.
3. Ahmed I, Nasreen S. Frequency of raised serum IgE level in childhood atopic dermatitis. J Pak Med Assoc. 2007; 57:431–434.
4. Kinet JP. The high-affinity IgE receptor (Fc epsilon RI): from physiology to pathology. Annu Rev Immunol. 1999; 17:931–972.
5. Binder CJ, Witztum JL. Is atherosclerosis an allergic disease? Circ Res. 2011; 109:1103–1104.
Article
6. Wang J, Cheng X, Xiang MX, Alanne-Kinnunen M, Wang JA, Chen H, He A, Sun X, Lin Y, Tang TT, Tu X, Sjöberg S, Sukhova GK, Liao YH, Conrad DH, Yu L, Kawakami T, Kovanen PT, Libby P, Shi GP. IgE stimulates human and mouse arterial cell apoptosis and cytokine expression and promotes atherogenesis in Apoe-/- mice. J Clin Invest. 2011; 121:3564–3577.
Article
7. Sicherer SH, editor. Food allergy: practical diagnosis and management. Boca Raton (FL): CRC Press Taylor & Francis Group;2013.
8. Siles RI, Hsieh FH. Allergy blood testing: a practical guide for clinicians. Cleve Clin J Med. 2011; 78:585–592.
Article
9. Brockow K, Garvey LH, Aberer W, Atanaskovic-Markovic M, Barbaud A, Bilo MB, Bircher A, Blanca M, Bonadonna B, Campi P, Castro E, Cernadas JR, Chiriac AM, Demoly P, Grosber M, Gooi J, Lombardo C, Mertes PM, Mosbech H, Nasser S, Pagani M, Ring J, Romano A, Scherer K, Schnyder B, Testi S, Torres M, Trautmann A, Terreehorst I. ENDA/EAACI Drug Allergy Interest Group. Skin test concentrations for systemically administered drugs: an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy. 2013; 68:702–712.
10. Bozbas H, Pirat B, Yildirir A, Eroglu S, Simsek V, Sade E, Atar I, Aydinalp A, Ozin B, Muderrisoglu H. Coronary microvascular function in patients with isolated systolic and combined systolic/diastolic hypertension. J Clin Hypertens (Greenwich). 2012; 14:871–876.
Article
11. Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR, Clegg LX. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol. 1997; 146:483–494.
Article
12. Naya M, Murthy VL, Blankstein R, Sitek A, Hainer J, Foster C, Gaber M, Fantony JM, Dorbala S, Di Carli MF. Quantitative relationship between the extent and morphology of coronary atherosclerotic plaque and downstream myocardial perfusion. J Am Coll Cardiol. 2011; 58:1807–1816.
Article
13. Tsukamoto T, Morita K, Naya M, Katoh C, Inubushi M, Kuge Y, Tsutsui H, Tamaki N. Myocardial flow reserve is influenced by both coronary artery stenosis severity and coronary risk factors in patients with suspected coronary artery disease. Eur J Nucl Med Mol Imaging. 2006; 33:1150–1156.
Article
14. Naya M, Tamaki N, Tsutsui H. Coronary flow reserve estimated by positron emission tomography to diagnose significant coronary artery disease and predict cardiac events. Circ J. 2015; 79:15–23.
Article
15. Ziadi MC, Dekemp RA, Williams KA, Guo A, Chow BJ, Renaud JM, Ruddy TD, Sarveswaran N, Tee RE, Beanlands RS. Impaired myocardial flow reserve on rubidium-82 positron emission tomography imaging predicts adverse outcomes in patients assessed for myocardial ischemia. J Am Coll Cardiol. 2011; 58:740–748.
Article
16. Murthy VL, Naya M, Foster CR, Hainer J, Gaber M, Di Carli G, Blankstein R, Dorbala S, Sitek A, Pencina MJ, Di Carli MF. Improved cardiac risk assessment with noninvasive measures of coronary flow reserve. Circulation. 2011; 124:2215–2224.
Article
17. Burke GL, Evans GW, Riley WA, Sharrett AR, Howard G, Barnes RW, Rosamond W, Crow RS, Rautaharju PM, Heiss G. Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study. Stroke. 1995; 26:386–391.
18. Campuzano R, Moya JL, García-Lledó A, Tomas JP, Ruiz S, Megías A, Balaguer J, Asín E. Endothelial dysfunction, intima-media thickness and coronary reserve in relation to risk factors and Framingham score in patients without clinical atherosclerosis. J Hypertens. 2006; 24:1581–1588.
Article
19. Bots ML, Baldassarre D, Simon A, de Groot E, O'Leary DH, Riley W, Kastelein JJ, Grobbee DE. Carotid intima-media thickness and coronary atherosclerosis: weak or strong relations? Eur Heart J. 2007; 28:398–406.
Article
20. Criqui MH, Lee ER, Hamburger RN, Klauber MR, Coughlin SS. IgE and cardiovascular disease. Results from a population-based study. Am J Med. 1987; 82:964–968.
21. Sinkiewicz W, Błazejewski J, Bujak R, Kubica J, Dudziak J. Immunoglobulin E in patients with ischemic heart disease. Cardiol J. 2008; 15:122–128.
22. Szczeklik A, Sladek K, Szczerba A, Dropinski J. Serum immunoglobulin E response to myocardial infarction. Circulation. 1988; 77:1245–1249.
Article
23. Korkmaz ME, Oto A, Saraçlar Y, Oram E, Oram A, Ugurlu S, Karamehmetoglu A, Karaagaoglu E. Levels of IgE in the serum of patients with coronary arterial disease. Int J Cardiol. 1991; 31:199–204.
Article
24. Szczeklik A, Dropiński J, Góra PF. Serum immunoglobulin E and sudden cardiac arrest during myocardial infarction. Coron Artery Dis. 1993; 4:1029–1032.
Article
25. Edston E, van Hage-Hamsten M. Immunoglobulin E, mast cell-specific tryptase and the complement system in sudden death from coronary artery thrombosis. Int J Cardiol. 1995; 52:77–81.
Article
26. Langer RD, Criqui MH, Feigelson HS, McCann TJ, Hamburger RN. IgE predicts future nonfatal myocardial infarction in men. J Clin Epidemiol. 1996; 49:203–209.
Article
27. Kovanen PT, Mänttäri M, Palosuo T, Manninen V, Aho K. Prediction of myocardial infarction in dyslipidemic men by elevated levels of immunoglobulin classes A, E, and G, but not M. Arch Intern Med. 1998; 158:1434–1439.
Article
28. Kushner I. The phenomenon of the acute phase response. Ann N Y Acad Sci. 1982; 389:39–48.
Article
29. Linneberg A, Jacobsen RK, Jespersen L, Abildstrøm SZ. Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality. J Allergy Clin Immunol. 2012; 129:413–419.
Article
30. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003; 107:363–369.
Article
31. Hamad A, Qureshi HJ, Roohi N. Assessment of C-reactive proteins in recently diagnosed type-1 diabetic children as a risk marker of early atherosclerosis. J Ayub Med Coll Abbottabad. 2014; 26:434–436.
32. van der Meer IM, de Maat MP, Kiliaan AJ, van der Kuip DA, Hofman A, Witteman JC. The value of C-reactive protein in cardiovascular risk prediction: the Rotterdam Study. Arch Intern Med. 2003; 163:1323–1328.
33. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet. 1998; 351:88–92.
Article
34. de Lemos JA, Hennekens CH, Ridker PM. Plasma concentration of soluble vascular cell adhesion molecule-1 and subsequent cardiovascular risk. J Am Coll Cardiol. 2000; 36:423–426.
Article